You can buy or sell Radius Health and other stocks, options, ETFs, and crypto commission-free!
Radius Health, Inc. Common Stock, also called Radius Health, is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. Read More The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 1
Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales
Radius Health, Inc. RDUS reported encouraging results for the fourth quarter of 2018, wherein loss was narrower than expected and sales beat estimates. Radius Health, Inc. Price, Consensus and EPS Surprise Radius Health, Inc. Price, Consensus and EPS Surprise | Radius Health, Inc. Quote The company reported a loss of $0.66 per share in the quarter, narrower than both the Zacks Consensus Estimate of a loss of $0.82 and the year-ago period’s loss of $1.36. Increase in revenues led to the narrower-than-anti...
Expected May 9, After Hours